Objective: Dolutegravir (DTG), a highly effective second-generation HIV integrase
inhibitor with high genetic barrier to resistance, has shown excellent tolerability and safety profiles in
clinical trials. However, some patients may experience neurological or psychiatric adverse effects
leading to DTG discontinuation.
Case Report: This report describes a case of 29-year-old woman who developed neurological adverse
events after starting the DTG-based antiretroviral therapy. Serum DTG concentrations were supratherapeutic
which has required a dosing interval adjustment. The findings of this case report suggest
that Therapeutic Drug Monitoring might be useful in individuals expressing unusual DTG